Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
The effects of 1.5-2 years oral administration of disodium (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on bone metabolism were studied in male and female rats. APD was mixed in the food at levels of 500, 2,000 and 10,000 ppm. A dose-dependent increase in metaphyseal bone was found, indicative of continued inhibition of bone and cartilage resorption. APD did not affect mineralization of bone and cartilage, primary bone formation, or periosteal apposition. A short-term metabolic balance study was performed to compare the effects of oral with subcutaneous APD. Absorption of APD was in the order of 0.2%. Oral APD increased absorption of phosphate, probably by complexation of calcium with APD. The excess absorbed phosphate increased phosphaturia and decreased urinary calcium.
D000284:Administration, Oral; D000818:Animals; D000886:Anthropometry; D001846:Bone Development / Q000187:drug effects*; D001862:Bone Resorption / Q000187:drug effects*; D001842:Bone and Bones / Q000033:anatomy & histology; D002118:Calcium / Q000652:urine; D004164:Diphosphonates / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D000077268:Pamidronate; D010710:Phosphates / Q000652:urine; D051381:Rats; D011919:Rats, Inbred Strains
D004164:Diphosphonates; D010710:Phosphates; D000077268:Pamidronate; D006909:Hydroxyproline; D002118:Calcium